NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has regained compliance with a Nasdaq listing requirement regarding stockholders' equity.

The firm, which makes microRNA-based diagnostic products, said that it received notification from the Nasdaq Listing Qualifications Staff that it is now in compliance with a requirement that it have $2.5 million in stockholders' equity in order to remain listed on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.